Bristol-Myers reports rise in 4th-quarter profit NEW YORK (AP) - Bristol-Myers Squibb Co. reported a 76 percent increase in the fourth-quarter profit Thursday, driven in part by sales of a recently-approved diabetes drug and hefty charges a year earlier, though the drugmaker still fell short of Wall Street's expectations. The company focused attention on rapid sales growth for its three-year-old injectable diabetes drug Onglyza. But results were dominated by the blood thinner Plavix, the world's second best-selling drug which loses U.S. patent protection this year. Net income rose to $852 million, or 50 cents per share, up from $483 million, or 28 cents per share. Excluding charges, adjusted profit was 53 cents per share. Total sales increased 7 percent to $5.45 billion. According to FactSet, analysts expected earnings per share of 55 cents on sales of $5.51 billion.